The effect of ciprofloxacin on doxorubicin cytotoxic activity in the acquired resistance to doxorubicin in DU145 prostate carcinoma cells
- PMID: 36071289
- DOI: 10.1007/s12032-022-01787-9
The effect of ciprofloxacin on doxorubicin cytotoxic activity in the acquired resistance to doxorubicin in DU145 prostate carcinoma cells
Abstract
The present study aimed to assess the influence of ciprofloxacin (CIP) against the doxorubicin (DOX)-resistant androgen-independent prostate cancer DU145 cells. The DOX-resistant DU145 (DU145/DOX20) cells were established by exposing DU145 cells to the increasing concentrations of DOX. The antiproliferative effect of CIP was examined through employing MTT, colony formation, and 3D culture assays. DU145/DOX20 cells exhibited a twofold higher IC50 value for DOX, an increased ABCB1 transporter activity, and some morphological changes accompanied by a decrease in spheroid size, adhesive and migration potential compared to DU145 cells. CIP (5 and 25 µg mL-1) resulted in a higher reduction in the viability of DU145/DOX20 cells than in DU145 cells. DU145/DOX20 cells were more resistant to CIP in 3D culture compared to the 2D one. No spheroid formation was observed for DU145/DOX20 cells treated with DOX and CIP combination. CIP and DOX, alone or in combination, significantly reduced the growth of DU145 spheroids. CIP in combination with 20 nM DOX prevented the colony formation of DU145 cells. The clonogenicity of DU145/DOX20 cells could not be estimated due to their low adhesive potential. CIP alone caused a significant reduction in the migration of DU145 cells and resulted in a more severe decrease in the wound closure ability of DOX-exposed ones. We identified that CIP enhanced DOX sensitivity in DU145 and DU145/DOX20 cells. This study suggested the co-delivery of low concentrations of CIP and DOX may be a promising strategy in treating the DOX-resistant and -sensitive hormone-refractory prostate cancer.
Keywords: Ciprofloxacin; Clonogenicity; Doxorubicin-resistant cells; Migration ability; Prostate cancer; Spheroid growth.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits Tumour Development in TRAMP Mice.Sci Rep. 2016 Aug 31;6:32062. doi: 10.1038/srep32062. Sci Rep. 2016. PMID: 27576789 Free PMC article.
-
Zinc oxide nanofluids: The influence of modality combinations on prostate cancer DU145 cells.J Cancer Res Ther. 2021 Apr-Jun;17(2):393-400. doi: 10.4103/jcrt.JCRT_232_17. J Cancer Res Ther. 2021. PMID: 34121683
-
Concentration-Dependent Dual Effects of Ciprofloxacin on SB-590885-Resistant BRAFV600E A375 Melanoma Cells.Chem Res Toxicol. 2019 Apr 15;32(4):645-658. doi: 10.1021/acs.chemrestox.8b00335. Epub 2019 Mar 14. Chem Res Toxicol. 2019. PMID: 30829029
-
Pleiotropic effects of probenecid on three-dimensional cultures of prostate cancer cells.Life Sci. 2021 Aug 1;278:119554. doi: 10.1016/j.lfs.2021.119554. Epub 2021 Apr 28. Life Sci. 2021. PMID: 33932444
-
Mitochondrial delivery of doxorubicin by triphenylphosphonium-functionalized hyperbranched nanocarriers results in rapid and severe cytotoxicity.Pharm Res. 2013 Nov;30(11):2832-42. doi: 10.1007/s11095-013-1111-7. Epub 2013 Aug 7. Pharm Res. 2013. PMID: 23921486
Cited by
-
Ciprofloxacin and Norfloxacin Hybrid Compounds: Potential Anticancer Agents.Curr Top Med Chem. 2024;24(7):644-665. doi: 10.2174/0115680266288319240206052223. Curr Top Med Chem. 2024. PMID: 38357952 Review.
-
Let's Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer.Int J Mol Sci. 2023 Mar 10;24(6):5293. doi: 10.3390/ijms24065293. Int J Mol Sci. 2023. PMID: 36982368 Free PMC article. Review.
References
-
- Chen J, Chen B, Zou Z, Li W, Zhang Y, Xie J, et al. Costunolide enhances doxorubicin-induced apoptosis in prostate cancer cells via activated mitogen-activated protein kinases and generation of reactive oxygen species. Oncotarget. 2017. https://doi.org/10.18632/oncotarget.22592 . - DOI - PubMed - PMC
-
- Li S, Yuan S, Zhao Q, Wang B, Wang X, Li K. Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it. Biomed Pharmacother. 2018. https://doi.org/10.1016/j.biopha.2018.02.055 . - DOI - PubMed
-
- Bai T, Liu Y, Li B. LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells. IUBMB Life. 2019. https://doi.org/10.1002/iub.2075 . - DOI - PubMed
-
- Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013. https://doi.org/10.1111/j.2042-7158.2012.01567.x . - DOI - PubMed
-
- Zahreddine H, Borden K. Mechanisms and insights into drug resistance in cancer. Front Pharmacol. 2013. https://doi.org/10.3389/fphar.2013.00028 . - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical